25.Issue 09 september 21 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 08, Issue : 09, September – 2021

Title:

25.AN OVERVIEW OF PARP INHIBITORS IN BRCA 1/2 MUTATED OVARIAN CANCER

Authors :

DR. DHARITRI G JOSHI, DR. G.L. PRABHUSHANKAR

Abstract :

Ovarian cancer being asymptomatic is leading to late diagnosis resulting in increased death rate worldwide. The development of platinum resistant ovarian cancer, research has paved the way for new class of drug called PARP inhibitors. PARP inhibitors [Poly (ADP-Ribose) polymerase inhibitors] are used in epithelial cell carcinoma, platinum resistant ovarian cancer, recurrent ovarian cancer etc. They act by inhibiting PARP proteins that are involved in DNA repair, finally resulting in cell death. Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib are the members that belong to the family of PARP inhibitors. These drugs vary in their route of administration, dose, toxicity profile, efficacy and pharmacokinetic parameters. This class of drugs majorly exhibits haematological and gastrointestinal adverse reactions. Most of these drugs causes Myelodysplastic syndrome/ Acute Myeloid Leukaemia and Embryo-foetal toxicity. These classes of drugs are contraindicated in lactating women, also these drugs shows wide changes in various laboratory parameters. Pharmacist plays a major role in monitoring the patient’s laboratory values, thereby modifying the dose of the drug in toxicities. The main role of a clinical pharmacist is dose adjustment in renal and hepatic impairment patients. It is also hypothesized that, these drugs exhibit resistance through the efflux of drug by p-gp transporters. Another concern with this class of drugs is development of secondary malignancy. This review summarizes the characteristics and uses of various drugs that belongs to PARP inhibitors.
KEYWORDS: Ovarian cancer, Epithelial cell carcinoma, PARP Inhibitors, Olaparib, Niraparib, Rucaparib.

Cite This Article:

Please cite this article in press Dharitri G Joshi et al, An Overview Of Parp Inhibitors In Brca 1/2 Mutated Ovarian Cancer., Indo Am. J. P. Sci, 2021; 08(9).

Number of Downloads : 10

References:

1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11: 287-99.
2. Danforth KN, Im TM, Whitlock EP. Addendum to screening of ovarian cancer: Evidence update Evidence Update for the US Preventive Services Task Force Reaffirmation Recommendation Statement. . Rockville, MD: AHRQ Publication No. 12-05165-EF4; 2012.
3. Shabir S, Gill PK. Global scenario on ovarian cancer – Its dynamics, relative survival, treatment, and epidemiology. Adesh Univ J Med Sci Res.2020;2(1):17-25.
4. Lima MA, Dos Santos L, Turri JA, Nonogaki S, Buim M, Lima JF, et al. Prognostic value of ADAMTS proteases and their substrates in epithelial ovarian cancer. Pathobiology.2016; 83:316-26.
5. Torpy JM, Burke AE, Golub RM. Ovarian cancer. J Am Med Assoc.2011; 305:2484-4.
6. Lefkowitz ES, Garland CF. Sunlight, Vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol.1994; 23:1133-6.
7. Medina-Franco H, Mejía-Fernández L. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages. Chin Clin Oncol. 2018;7(6):57–.
8. Bhargav B. Consensus document for management of epithelial ovarian cancer. New Delhi: Division of Publication and Information on behalf of the Secretary DHR & DG, ICMR; 2019.
9. Bahena-González A, Toledo-Leyva A, Gallardo-Rincón D. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. Chin Clin Oncol. 2020; 9(4):51-.
10. Jiang X, Li W, Li X, Bai H, Zhang Z . Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manage and Res.2019;11:4371–90.
11. Cortez JA, Tudrej P, Kujawa KA, Lisowska KM. Advances in Ovarian Cancer Therapy. Cancer Chemother. Pharmacol . 2018; 81:17-38. doi:https://doi.org/10.1007/s00280-017-3501-8.
12. Deeks ED. Olaparib: first global approval. Drugs. 2015; 75:231–40. doi:10.1007/s40265-015-0345-6.
13. Scott LJ. Niraparib: first global approval. Drugs. 2017; 77:1029–34. doi:10.1007/s40265-017-0752-y.
14. Syed YY. Rucaparib: first global approval. Drugs. 2017; 77:585–92. doi:10.1007/s40265-017-0716-2.
15. Lynparza 50 mg hard capsules [Internet]. EU summary of product characteristics. Astrazeneca; 2014 [cited 2021 Jul 15]. Available from: https://www.ema.europa.eu/documents/product-information/lynparza-epar productinformation_en.pdf
16. Lynparza (Olaparib) capsules, for oral use [Internet].US prescribing information. AstraZeneca Pharmaceuticals LP; 2014 [cited 2021 Jul 15] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206162s011lbl.pdf .
17. Lynparza (Olaparib) tablets, for oral use [Internet].FDA approved Olaparib tablets for maintenance treatment in ovarian cancer. AstraZeneca Pharmaceuticals LP; 2014[cited 2021 Jul 15] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s005lbl.pdf .
18. Lynparza 100 mg and 150 mg tablet [Internet]. EU CHMP post-authorisation summary of positive opinion for lynparza. AstraZeneca AB; 2018[cited 2021 Jul 15] Available from: https://www.ema.europa.eu/documents/smop/chmppost-authorisation-summary-positive-opinion-lynparza_en.pdf
19. Lynparza (Olaparib) tablets, for oral use [Internet]. US prescribing information. AstraZeneca Pharmaceuticals LP; 2018 [cited 2021 Jul 15]Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf.
20. Prescribing information for rubraca (Rucaparib) tablets, for oral use [Internet]. Clovis Oncology Inc; 2016[cited 2021 Jul 15] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf
21. Rubraca tablet [Internet]. EU CHMP summary of positive opinion for rubraca. Clovis Oncology Inc; 2018[cited 2021 Jul 15] Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca
22. Zejula(Niraparib)[Internet]: US prescribing information. Tesaro; 2017[cited 2021 Jul 15] Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf
23. Zejula 100 mg hard capsules [Internet]: EU summary of product characteristics.Tesaro; 2017[cited 2021 Jul 15]. Available from: https://www.ema.europa.eu/documents/product-information/zejula-epar-product-information_en.pdf .
24. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33:244-50.
25. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366:1382-92.
26. Mirza MR, Monk BJ, Herrstedt J et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016; 375:2154-64.
27. Rouleau M, Patel A, Hendzel MJ et al. PARP inhibition: PARP1 and beyond [J]. Nat Rev Cancer. 2010; 10(4):293-301.
28. Sancar A, Lindsey-Boltz L, Ünsal-Kaçmaz K, Linn S. Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints. Annu Rev Biochem. 2004; 73(1):39-85.
29. Integrated genomic analyses of ovarian carcinoma. Nature.2011; 474(7353):609-615.
30. Bast R, Hennessy B, Mills G. The biology of ovarian cancer: new opportunities for translation. Nat Rev Canc. 2009;9(6):415-28.
31. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni-Salvatore G, Facchini G. Chemotherapy in epithelial ovarian cancer.Cancer Lett.2011; 303(2):73–83.
32. Curtin JN. DNA repair dysregulation from cancer driver to therapeutic target, Nat Rev Cancer.2012; 12(12):801-17.
33. Brown J, O’Carrigan B, Jackson S, Yap T. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discovery. 2016; 7(1):20-37.
34. Liu C, Vyas A, Kassab M, Singh A, Yu X. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acid Res. 2017; 45(14):8129-41.
35. Sonnenblick A, Azambuja ED , Azim HA, Piccart M. An update on PARP inhibitors – moving to adjuvant setting. Nat Rev Clin Oncol. 2015; 12(1):27-41
36. Lynparza (Olaparib). Product Monograph including patient medication information. [Internet]. Mississauga, Ontario: AstraZeneca Canada Inc; 2021 [cited 18 July 2021]. Available from: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/lynparza-tablets-product-monograph-en.pdf.
37. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza M et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New Engl J of Med. 2019; 381(25):2391-402.DOI: 10.1056/NEJMoa1910962.
38. Antolin A, Ameratunga M, Banerji U, Clarke P, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep.2020; 10: 2585. https://doi.org/10.1038/s41598-020-59074-4.
39. Van Andel, L., Rosing, H., Zhang, Z. et al. Determination of the absolute oral bioavailability of Niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol.2018; 81:39–46. https://doi.org/10.1007/s00280-017-3455-x
40. Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM. Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist. 2020; 25(1):109-19. doi:10.1634/theoncologist.2019-0229.
41. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-58.
42. Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018; 29(6):1366-76.
43. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019; 20(1):15-28.
44. Zejula (Niraparib) [Internet]: Package insert. Waltham, MA: Tesaro; 2017[cited 2021 Jul 19]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf
45. Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. Clin Pharmacol Ther. 2019; 105(1):229-241. doi:10.1002/cpt.1103.
46. Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor. Clin Transl Sci. 2019;12(1):58-65. doi:10.1111/cts.12600.
47. Talzenna (Talaoparib) capsules for oral use [Internet]: Prescribing information. New York: Pfizer Inc; 2018[cited 2021 Jul 20].
48. O’Cearbhaill RE. Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology (Williston Park). 2018; 32(7):339-43.
49. Moore KN, Monk BJ. Patient counseling and management of symptoms during Olaparib therapy for recurrent ovarian cancer. Oncologist. 2016;21(8):954-63. doi:10.1634/theoncologist.2015-0268.
50. Patibandla NS, Monga DK. Niraparib – A promising drug with hematological toxicity. J Oncol Pharm Pract. 2019 Oct;25(7):1749-1753. doi: 10.1177/1078155218800156. Epub 2018 Oct 6. PMID: 30293481.
51. Coleman, Robert L et al. “Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) vol. 390, 10106 (2017): 1949-61. doi:10.1016/S0140-6736(17)32440-6.
52. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2 mutated cancers. Nature.2008; 451(7182):1116-20.
53. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1- deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum durgs [J]. PROC Natl Acad Sci USA, 2008,105(44):17079-84.
54. Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer.2011;30(7):460-71.
55. Drew Y, De Jonge M, Hong S-H, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm), platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol Oncol. 2018; 149(1):246-47.
56. Konstantinopoulos PA, Munster P, Forero-Torez, et al. TOPACIO: preliminary activity and safety (pts) in patients with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab. J Clin Oncol. 2018; 36(15 suppl):106-106.
57. PARP Inhibitors as Initial Treatment for Ovarian Cancer [Internet]. National Cancer Institute. 2021 [cited 28 July 2021]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2019/parp-inhibitors-ovarian-cancer-initial-treatment
58. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med.2019; 381: 2403–15.
59. K D, Armstrong. Use of PARP inhibitors for ovarian cancer. J Natl Compr Canc Netw. 2021; 19(5.5):636–8. doi: 10.6004/jnccn.2021.5013.
60. Nizialek E, Antonarakis ES. PARP inhibitors in metastatic prostate cancer:Evidence to date. Canc Mang Res. 2020;12: 8105-7.
61. Jang A, Sartor O, Barata P, Paller C. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Cancers. 2020;12(11):3467.
62. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011; 105(8):1114-22.
63. Wiggans AJ, Cass GKS, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews.2015 [cited 28 July 2021], Issue 5. Art. No.: CD007929. Accessed from:https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007929.pub3/full
64. To C, Kim E, Royce D, Williams C, Collins R, Risingsong R et al. The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice. Cancer Prev Res. 2014;7(7):698-707.
65. Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V et al. Ovarian cancer treatments strategy: Focus on PARP inhibitors and immune check point inhibitors. Cancers. 2021; 13(6):1298.
66. Olabisi OA, Soto-Nieves N, Nieves E, et al. Regulation of transcription factor.NFAT by ADP-ribosylation. Mol Cell Biol. 2008;28:2860-71.
67. Ghonim MA, Pyakurel K, Ibba SV, et al. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med. 2015;13: 225.
68. Rosado MM, Bennici E, Novelli F, Pioli C. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology. 2013;139: 428-37.
69. Mulligan AM, Raitman I, Feeley L, et al. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res. 2013;19: 336-46.
70. Xue C, Xu Y, Ye W, et al. Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol. 2020; 157: 222-33.
71. Zerfaoui M, Errami Y, Naura AS, et al. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF kappa-B upon TLR4 stimulation. J Immunol. 2010; 185: 1894-902.
72. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem. 2001; 276:45588-97.
73. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015; 66:455-70.
74. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012; 72:5588-99.
75. Paradiso A, Andreopoulou E, Conte P, Eniu A, Saghatchian M. PARP Inhibitors in Breast Cancer: Why, How, and When?. Breast Care. 2018; 13(3):216-219.
76. Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z et al. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clinical Medicine Insights: Oncology. 2021;15:117955492199628.
77. Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med 2017;9:eaal4922.
78. Gien L, Mackay H. The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. J of Oncol. 2010; 2010:1-6.
79. Audebert M, et al. Involvement of poly (ADPribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem.2004; 279(53):55117–126.
80. Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oza AM, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet.2017;390: 1949-61.
81. Usmani H, Hussain SA, Sheikh A. PARP inhibitors: current status and implications for anticancer therapeutics. Infe ag and canc.2013:8:46.
82. Grewal K, Grewal K, Tabbar I. PARP Inhibitors in Prostate Cancer. Anticanc Res. 2021; 41(2):551-6.
83. Xie H, Wang W, Xia B, Jin W, Lou G. Therapeutic applications of PARP inhibitors in ovarian cancer. Biomed Pharmacother. 2020; 127:110204.